Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Tuesday, 24 April 2007

Press Release of the Week

Posted on 23:39 by Unknown
To paraphrase The Late Show With David Letterman (and Perry Como), we get press releases! Stacks and stacks of press releases!

And don't get us wrong, The IN VIVO Blog is all for a good pun--sometimes, even a bad one. But this release from Datamonitor is a bit much. Roll your eyes with us, below.





If we hadn't regularly received press releases from this guy before, we'd guess even his name was in on the act. In any case, let this be the first in an ongoing series highlighting the good, the bad and the ugly (and the pun-riffic) of biopharma industry press releases. As if you hadn't seen enough.
Email ThisBlogThis!Share to XShare to Facebook
Posted in PR, Press Release of the Week | No comments
Newer Post Older Post Home
View mobile version

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Take the Money…or Let it Roll?
    In his talk introducing the top-10 most licensable oncology drugs at the Therapeutic Alliances conference last Friday, Ben Bonifant of Campb...
  • $80 million upfront? About Average
    So Synta’s PR firm were pushing today’s deal with GlaxoSmithKline at us as “one of the biggest product deals this year” and indeed “among t...
  • Beijing Boost for Japanese Encephalitis Vaccine
    China has been preparing feverishly for the Beijing Olympics for years to showcase its new world position and economic power. China's co...
  • Reporting on Exubera: an A-Buse
    Many analysts have questioned the potential of Pfizer’s inhaled insulin, Exubera . Nonetheless, it was more than surprising to see the comme...
  • The Best Defense Is a Good Offense, Or Something Like That
    Merck and Schering-Plough put out a release a few minutes ago responding to critics of ENHANCE and the trial results' fallout: WHITEHOU...
  • Public Confidence in Drug Safety: Solution is in "Plane" Sight
    Active surveillance and data mining are scary, right? It is common wisdom that these tools in the hands of academics, health plans and regul...
  • Addex Ups Dealmaking Ante
    Addex Pharma today took a step up the dealmaking ladder , partnering its pre-IND positive allosteric modulator ADX63365 and back-up compound...
  • Pfizer UK Gets “Closer to Customers”
    “Increased patient safety” drove Pfizer’s recent deal with UK wholesaler Alliance UniChem, according to the partners. But no one’s buying th...
  • Another Look at Asia
    As a small follow up to our post last week on Sofinnova Partners' hiring an Asia-focused professional, VentureWire Lifescience reported...
  • Deals of the Week: "King of Pain" Edition
    Admittedly, it's been a quiet week for biz dev in pharma land. The big news has been clinical. On the positive side, the diabetes triumv...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ▼  April (16)
      • Sleep Tight, Kids!
      • GSK: Seeding More CEDDs?
      • Aim Low?
      • Bristol as Biotech
      • Bristol Continues Late-Stage Asset Sale
      • Back in the day
      • Press Release of the Week
      • MedImmune Investors Get Paid
      • Antisoma Licenses AS1404: The Sequel
      • The More The Money-er
      • More Insulin Problems
      • Strategic Alternatives: MedImmune Edition
      • Amgen's CFO: Escaping a Sinking Ship?
      • Take a Deep Breath, Pfizer, and Think Again
      • Everybody Plays, Everybody Wins
      • Novartis' Irritable Blockbuster Syndrome
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile